Accendra Health schedules November 5 results for Accendra Health stock

Published on 10/24/2026 at 19:44 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q2 revenue was USD 613.23 million, with guidance at USD 2.45 billion to USD 2.55 billion. Accendra Health stock costs EUR 0.19 on October 24, 2026.

Reporting date and financial pressure

Accendra Health announced a November 5, 2026 release date for third-quarter results on October 22, 2026.
Second-quarter revenue was USD 613.23 million, while full-year revenue guidance was USD 2.45 billion to USD 2.55 billion.
Accendra Health stock costs EUR 0.19 at Lang & Schwarz on October 24, 2026 at 1:04 p.m. CEST.
Market capitalization was USD 16.7 million as of October 23, 2026.

ACH, US6907321029, Illustration mit AI erstellt.

Accendra Health (US6907321029) scheduled its third-quarter 2026 results for November 5, 2026, extending the company calendar beyond a difficult second quarter. Business Wire reported the date on October 22, 2026. Accendra Health stock was trading at EUR 0.19 at Lang & Schwarz on October 24, 2026 at 1:04 p.m. CEST.

Second-quarter loss sets the backdrop

Accendra Health reported second-quarter revenue of USD 613.23 million for the period ended June 30, 2026, down from USD 627.78 million in the first quarter. Net loss attributable to common shareholders reached USD 89.07 million, compared with a USD 6.47 million loss in the first quarter. The figures come from the company's second-quarter earnings materials carried in the Yahoo Finance transcript.

Management's full-year 2026 outlook calls for revenue of USD 2.45 billion to USD 2.55 billion and adjusted EBITDA of USD 300 million to USD 320 million. The second-quarter operating loss therefore sits alongside a recovery plan that depends on cost reductions, payer collections and stronger fourth-quarter activity.

NYSE compliance adds a market risk

On October 6, 2026, Accendra Health received a NYSE notice because its average closing price had stayed below USD 1.00 for 30 consecutive trading days, according to Business Wire. The company has six months to regain compliance and said a reverse split could be considered if needed, subject to shareholder approval.

Nasdaq reported on October 23, 2026 that the average one-year analyst target had fallen to USD 1.29 from USD 1.54 on September 29, 2026. The target revision puts the operating outlook and the listing issue into the same investor calculation.

Price position and valuation

Accendra Health's NYSE price closed at USD 0.22 on October 23, 2026. The 52-week range was USD 0.19 to USD 5.60, placing the close USD 0.03 above the low and USD 5.38 below the high. Market capitalization stood at USD 16.7 million, with trading volume of 2,046,101 shares.

Comparison with peers

Accendra Health: P/E -0.06, market capitalization USD 16.7 million.

Henry Schein (Nasdaq, USD): down 1.21 percent, P/E 24.77, market capitalization USD 9.5 billion.

Cardinal Health (NYSE, USD): down 2.37 percent, P/E 34.52, market capitalization USD 57.8 billion.

November results are the next test

The November 5 release will show whether the revenue range and adjusted EBITDA outlook remain intact after the second-quarter loss. It will also give investors a new measure of progress toward the NYSE's USD 1.00 minimum price requirement.

Accendra Health was trading at EUR 0.19 at Lang & Schwarz on October 24, 2026 at 1:04 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Accendra Health stock.